ChrisHTakimotoMD

PubMed

• 164 citations
  Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies.
  Mark P. Chao, Chris H. Takimoto, Dong Dong Feng, Mckenna Kelly Marie, Phung Gip, Jie Liu, Jens-Peter Volkmer, Irving L. Weissman, Ravindra Majeti> ;Frontiers in Oncology. 2020 Jan 22
• 16 citations
  Improving attribution of adverse events in oncology clinical trials.
  Goldy C. George, Pedro C. Barata, Alicyn Campbell, Alice P. Chen, Jorge E. Cortes, David M. Hyman, Lee Jones, Thomas Karagiannis, Sigrid Klaar, Jennifer Le-Rademacher,...> ;Cancer Treatment Reviews. 2019 Jun 1
• 65 citations
  The Macrophage 'Do not eat me' signal, CD47, is a clinically validated cancer immunotherapy target.
  Chris H. Takimoto, M.P. Chao, C. Gibbs, M.A. McCamish, J. Liu, James Y. Chen, Ravi Majeti, Irving L. Weissman> ;Annals of Oncology. 2019 Mar 1
• 629 citations
  CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.
  Ranjana H. Advani, Ian W. Flinn, Leslie Popplewell, Andres Forero, Nancy L. Bartlett, Nilanjan Ghosh, Justin Kline, Mark Roschewski, Ann S. LaCasce, Graham P. Collins,...> ;The New England Journal of Medicine. 2018 Oct 31
• 1 citations
  Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules.
  Kamalesh Kumar Sankhala, Chris H. Takimoto, Alain C. Mita, Henry Xiong, Jordi Rodon, Amir Mehrvarz Sarshekeh, K. Burns, Kenzo Iizuka, Scott Kopetz> ;Investigational New Drugs. 2019 Feb 1
• 304 citations
  First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.
  Branimir I. Sikic, Nehal Lakhani, Amita Patnaik, Sumit A. Shah, Sreenivasa R Chandana, Drew W. Rasco, A. Dimitrios Colevas, Timothy J. O'Rourke, Sujata Narayanan, Kyri...> ;Journal of Clinical Oncology. 2016 May 20
• 15 citations
  Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing.
  Mina Nikanjam, Clinton F. Stewart, C. H. Takimoto, Timothy W. Synold, Orren Beaty, Maryam Fouladi, Edmund V. Capparelli> ;Cancer Chemotherapy and Pharmacology. 2015 Jan 4
• 35 citations
  A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors
  Muhammad Wasif Saif, Chris H. Takimoto, Monica M. Mita, Udai Banerji, Nicole Lamanna, Januario E. Castro, Susan O'Brien, Christopher Stogard, Daniel D. Von Hoff> ;Clinical Cancer Research. 2014 Jan 15
• 11 citations
  Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788
  José Baselga, Alain C. Mita, Patrick Schöffski, Herlinde Dumez, Frederico Rojo, Josep Tabernero, Clifford DiLea, William Mietlowski, Christie Low, J. Huang, Margaret D...> ;Clinical Cancer Research. 2012 Nov 15
• 2 citations
  Metabolism of patupilone in patients with advanced solid tumor malignancies
  Kevin R. Kelly, Markus Zollinger, Frédéric Lozac'h, Eugene Tan, Alain C. Mita, Felix Waldmeier, Patrick Urban, Suraj Anand, Yanfeng Wang, Piet Swart, Chris H. Takimoto...> ;Investigational New Drugs. 2012 Jul 18
• 51 citations
  Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group ...
  Patricia LoRusso, Karthik Venkatakrishnan, Ramesh K. Ramanathan, John Sarantopoulos, Daniel Mulkerin, Stephen Shibata, Anne Hamilton, Afshin Dowlati, Sridhar Mani, Mic...> ;Clinical Cancer Research. 2012 May 15
• 10 citations
  A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC).
  J. Rodon, Charlotte Jacobs, Quincy Chu, Eric K. Rowinsky, Arturo Lopez-Anaya, Chris H. Takimoto, Heather A. Wakelee> ;Cancer Chemotherapy and Pharmacology. 2012 Mar 1
• 15 citations
  The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung c...
  Heather A. Wakelee, Chris H. Takimoto, Arturo Lopez-Anaya, Quincy Chu, Gary Middleton, D. Dunlop, Rodryg Ramlau, Natasha B. Leighl, Eric K. Rowinsky, Desiree Hao, Petr...> ;Cancer Chemotherapy and Pharmacology. 2012 Feb 1
• 28 citations
  Heat shock proteins: a potential anticancer target.
  Kamalesh Kumar Sankhala, Monica M. Mita, Alain C. Mita, Chris H. Takimoto> ;Current Drug Targets. 2011 Nov 30
• 14 citations
  Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors
  Muhammad Wasif Saif, John Sarantopoulos, Amita Patnaik, Anthony W. Tolcher, Chris H. Takimoto, Murali Beeram> ;Cancer Chemotherapy and Pharmacology. 2011 May 6
• 31 citations
  Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Gr...
  Ticiana Leal, Scot C. Remick, Chris H. Takimoto, Ramesh K. Ramanathan, Angela M. Davies, Merrill J. Egorin, Anne Hamilton, P. LoRusso, Stephen Shibata, Heinz-Josef Len...> ;Cancer Chemotherapy and Pharmacology. 2011 Apr 9
• 4 citations
  Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial.
  Apostolia Maria Tsimberidou, Chris H.M. Takimoto, Stacy L. Moulder, Cynthia Uehara, Monica M. Mita, Alain C. Mita, Patrick Urban, Eugene Tan, Yanfeng Wang, David Vinin...> ;Molecular Cancer Therapeutics. 2011 Jan 1
• 24 citations
  A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment
  Christopher Sweeney, Chris H. Takimoto, Leslie Wood, Jennifer M. Porter, William Tracewell, Mona Darwish, Denise D’Andrea, Scot C. Remick> ;Cancer Chemotherapy and Pharmacology. 2010 Jul 1
• 86 citations
  Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors
  Alain C. Mita, Chris H. Takimoto, Monica M. Mita, Anthony W. Tolcher, Kamalesh Kumar Sankhala, John Sarantopoulos, Manuel Valdivieso, Leslie Wood, Erik Rasmussen, Yu N...> ;Clinical Cancer Research. 2010 Jun 1
• 22 citations
  Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients
  Chee M. Ng, S. Bai, Chris H. Takimoto, M. T. Tang, Anthony W. Tolcher> ;Cancer Chemotherapy and Pharmacology. 2010 Jan 1
• 8 citations
  Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development.
  Chris H. Takimoto> ;European Journal of Cancer. 2009 Sep 1
• 410 citations
  Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas
  Robert G. Maki, David R. D'Adamo, Mary L. Keohan, Michael Saulle, Scott M. Schuetze, Samir D. Undevia, Michael B. Livingston, Matthew M. Cooney, Martee L. Hensley, Mon...> ;Journal of Clinical Oncology. 2009 Jul 1
• 20 citations
  Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies.
  Monica M. Mita, Alain C. Mita, John Sarantopoulos, Chris H. Takimoto, Eric K. Rowinsky, Ofelia Romero, Patrizia Angiuli, Cecilia Allievi, Amy J. Eisenfeld, Claire F. V...> ;Cancer Chemotherapy and Pharmacology. 2009 Jul 1
• 111 citations
  A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies
  Sanjay Goel, Alain C. Mita, Monica M. Mita, Eric K. Rowinsky, Quincy Siu-Chung Chu, Nancy Wong, Christopher DesJardins, Fang Fang, Mendel Jansen, Dale E. Shuster, Srid...> ;Clinical Cancer Research. 2009 Jun 15
• 2 citations
  Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies
  Chia Chi Lin, Muralidhar Beeram, Eric K. Rowinsky, Chris H. Takimoto, Chee M. Ng, Charles E. Geyer, Louis Denis, Johann S. De Bono, Desirée Hao, Anthony W. Tolcher, Su...> ;Cancer Chemotherapy and Pharmacology. 2009 May 16
• Join now to see all

Abstracts/Posters

• An All Antibody Approach for Conditioning Bone Marrow for Hematopoietic Stem Cell Transplantation with Anti-cKIT and Anti-CD47 in Non-Human Primates
  Chris H Takimoto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
  Chris H Takimoto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019